Rocket Pharmaceuticals (NASDAQ:RCKT) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.11, Fidelity Earnings reports.
NASDAQ RCKT traded up $1.20 during trading on Friday, hitting $16.36. 171,500 shares of the stock traded hands, compared to its average volume of 286,469. The company has a market capitalization of $729.55 million, a P/E ratio of -8.66 and a beta of 2.74. The firm has a 50-day simple moving average of $12.96 and a 200-day simple moving average of $14.19. The company has a quick ratio of 17.48, a current ratio of 17.48 and a debt-to-equity ratio of 0.18. Rocket Pharmaceuticals has a 12-month low of $10.75 and a 12-month high of $20.79.
Several research firms recently issued reports on RCKT. William Blair reiterated a “buy” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, September 10th. ValuEngine cut Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Zacks Investment Research cut Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 26th. Oppenheimer cut their target price on Rocket Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Finally, Cowen reiterated a “buy” rating on shares of Rocket Pharmaceuticals in a research report on Thursday. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $28.33.
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.
Recommended Story: Key terms to understand channel trading
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.